<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822494</url>
  </required_header>
  <id_info>
    <org_study_id>PCK-02</org_study_id>
    <nct_id>NCT03822494</nct_id>
  </id_info>
  <brief_title>CyberKnife Dose Escalation Prostate Cancer Trial</brief_title>
  <acronym>CK-DESPOT</acronym>
  <official_title>CyberKnife Dose Escalation for Unfavorable and High-risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crozer-Keystone Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crozer-Keystone Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate&#xD;
      cancer. Multiple single institution experiences suggest high biochemical control rates with&#xD;
      acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type&#xD;
      prostate cancer is less convincing. CyberKnife-SBRT (CK-SBRT) can be used to escalate&#xD;
      radiation dose delivery to the prostate while sparing normal tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal radiation schedule for the curative treatment of prostate cancer remains unknown.&#xD;
      Prostate cancer patients receiving radiation therapy are typically treated 5 days per week&#xD;
      for 8-9 weeks. Recent data suggest that large radiation fraction sizes are radio-biologically&#xD;
      favorable over lower fraction sizes in prostate cancer radiotherapy. The sensitivity of a&#xD;
      tumor or normal tissue to fraction size of radiation can be approximated by the alpha-beta&#xD;
      ratio. It has been suggested that the alpha/beta ratio for prostate cancer is actually as low&#xD;
      as 1.5 implying that the current radiation therapy paradigm for prostate cancer treatment&#xD;
      might be fundamentally flawed, as high fraction sizes would be expected to damage tumor more&#xD;
      readily.&#xD;
&#xD;
      Typical prostate SBRT doses do not appear to have similar efficacy in higher risk prostate&#xD;
      cancer suggesting even higher doses are required. Many techniques including dose escalated&#xD;
      external beam radiation therapy (EBRT), proton therapy (PT) and brachytherapy have been&#xD;
      employed to increase dose to the prostate. Data from the ASCEND-RT trial utilizing low dose&#xD;
      rate brachytherapy boost showed a dramatic 21% improvement in biochemical control at 9 years&#xD;
      favoring brachytherapy boost compared to conventional dose escalated EBRT radiation therapy.&#xD;
      However, no corresponding benefit was identified in overall survival, incidence of bone&#xD;
      metastases or prostate cancer specific mortality while a 3 fold increase in late urinary&#xD;
      toxicity was noted.&#xD;
&#xD;
      SBRT is well tolerated with minimal acute and late side effects. In this protocol, CK-SBRT&#xD;
      will be used to target the microscopic and gross disease in the prostate, seminal vesicles.&#xD;
      An escalated dose of 40 Gy in 5 fractions will be delivered to the entire target volume while&#xD;
      any nodules visible within the prostate gland on endorectal MRI will receive 50 Gy in 5&#xD;
      fractions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Anticipated">July 12, 2028</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bladder and Rectal Toxicity using NCI common toxicity criteria version 4.0</measure>
    <time_frame>24 Months</time_frame>
    <description>Genitourinary or Bowel Toxicity as a result of radiation therapy will be reported using</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical Disease Free Survival</measure>
    <time_frame>24 Months</time_frame>
    <description>Time in months from completion of SBRT to biochemical failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of local control</measure>
    <time_frame>24 Months</time_frame>
    <description>time in months from SBRT completion to local failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Failure</measure>
    <time_frame>24 Months</time_frame>
    <description>time in months from SBRT completion to distant failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>24 Months</time_frame>
    <description>time in months from the date that the patient is determined to be free of disease to the date of known disease recurrence for any measure of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Survival</measure>
    <time_frame>24 Months</time_frame>
    <description>time in months from completion of SBRT to death due to prostate cancer, other causes with active malignancy, or complications from treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>ime in months from SBRT completion until death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Prostate Neoplasm</condition>
  <arm_group>
    <arm_group_label>Dose Escalated CyberKnife SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CyberKnife SBRT</intervention_name>
    <description>Radiation Therapy</description>
    <arm_group_label>Dose Escalated CyberKnife SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate diagnosed within 360 days of&#xD;
             enrollment.&#xD;
&#xD;
          -  Prostate Specific Antigen (PSA) documented within 90 days prior to registration.&#xD;
&#xD;
          -  Clinical staging completed within 90 days of registration.&#xD;
&#xD;
          -  No Nodal or Distant Metastases documented on CT or MRI of the pelvis and bone scan.&#xD;
&#xD;
          -  Unfavorable Risk Prostate Carcinoma as Described is documented.&#xD;
&#xD;
          -  No prior pelvic radiotherapy.&#xD;
&#xD;
          -  No prior Trans-urethral resection of the prostate (TURP).&#xD;
&#xD;
          -  Prostate volume &lt; 100 cc&#xD;
&#xD;
          -  American Urologic Association (AUA) score &lt; 20&#xD;
&#xD;
          -  No recent (within 5 years) or concurrent cancers other than non-melanoma skin cancers.&#xD;
&#xD;
          -  Patient must have no medical or psychiatric illnesses that would interfere with&#xD;
             treatment or follow-up.&#xD;
&#xD;
          -  No implanted hardware adjacent to the prostate that would prohibit appropriate&#xD;
             treatment planning and treatment delivery is allowed.&#xD;
&#xD;
          -  Candidate for rectal spacer placement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other cancer diagnosis other than non-melanoma skin cancer with 5 years&#xD;
&#xD;
          -  Prostate size greater than 100cc&#xD;
&#xD;
          -  AUA greater than 20&#xD;
&#xD;
          -  Implanted hardware impacting imaging&#xD;
&#xD;
          -  Metastatic prostate cancer&#xD;
&#xD;
          -  Contraindication to hormone therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biological males with prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rachelle Lanciano, MD</last_name>
    <phone>610-446-6850</phone>
    <email>rachelle.lanciano@crozer.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Good, RN</last_name>
    <phone>610-446-6850</phone>
    <email>mgood@allianceoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Crozer Keystone Health System/Philadelphia CyberKnife Center</name>
      <address>
        <city>Havertown</city>
        <state>Pennsylvania</state>
        <zip>19083</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shilecion Cooper, RN</last_name>
      <phone>610-446-6850</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Crozer-Keystone Health System</investigator_affiliation>
    <investigator_full_name>Rachelle Lanciano M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>radiation therapy</keyword>
  <keyword>Cyberknife</keyword>
  <keyword>SBRT</keyword>
  <keyword>Protons</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03822494/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

